# Alnylam Pharmaceuticals (ALNY) — Earnings

ALNY · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/alny/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | $1.21 |
| EPS estimate | $1.63 |
| EPS surprise | −25.78% |
| Revenue surprise | −2.36% |
| Revenue | $1.3B |
| Revenue estimate | $1.3B |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/40ba53db-7353-850b-13da-a18b22c9193d.html) |

Alnylam Pharmaceuticals reported Q2 2026 results on July 30, 2026. Earnings per share were $1.21, missing the $1.63 estimate by 25.78%. Revenue was $1.3 billion, in line with the consensus and the highest in the table. Revenue rose about 68% from $773.7 million in Q2 2025, when Alnylam posted a loss of $0.51 per share.

The table shows a shift from losses to profits. Fifteen of the 20 quarters were losses, the deepest $3.32 per share in Q3 2022. The annual loss narrowed from $9.29 per share in 2022 to $3.56 in 2023 and $2.17 in 2024, and 2025 ended with a profit of $1.71. Apart from Q3 2023, at $1.15, profits began in Q3 2025 and have held for four straight quarters. Annual revenue rose from about $1.04 billion in 2022 to about $3.67 billion in 2025. Against estimates there were 11 beats and 9 misses, alternating in the last four quarters.

Alnylam has reported Q3 results between October 27 and November 2 in each of the past five years, which points to late October or early November 2026. The next report will show whether profits continue for a fifth straight quarter.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | $1.63 | $1.21 | -25.78% | $1.3B | $1.3B |
| Q1 2026 | Apr 30, 2026 | $0.90 | $1.51 | 68.72% | $1.1B | $1.2B |
| Q4 2025 | Feb 12, 2026 | $1.16 | $0.82 | -29.06% | $1.1B | $1.1B |
| Q3 2025 | Oct 30, 2025 | $0.56 | $1.84 | 227.99% | $959.4M | $1.2B |
| Q2 2025 | Jul 31, 2025 | −$0.54 | −$0.51 | 6.20% | $662.9M | $773.7M |
| Q1 2025 | May 1, 2025 | −$0.89 | −$0.44 | 50.56% | $585.1M | $594.2M |
| Q4 2024 | Feb 13, 2025 | −$0.59 | −$0.65 | -9.78% | $582.6M | $593.2M |
| Q3 2024 | Oct 31, 2024 | −$0.92 | −$0.87 | 5.08% | $532.9M | $500.9M |
| Q2 2024 | Aug 1, 2024 | −$1.07 | −$0.13 | 87.82% | $447.2M | $659.8M |
| Q1 2024 | May 2, 2024 | −$1.12 | −$0.52 | 53.41% | $428.0M | $494.3M |
| Q4 2023 | Feb 15, 2024 | −$1.19 | −$1.10 | 7.28% | $436.9M | $439.7M |
| Q3 2023 | Nov 2, 2023 | −$1.45 | $1.15 | 179.55% | $396.8M | $750.5M |
| Q2 2023 | Aug 3, 2023 | −$1.51 | −$2.21 | -46.76% | $332.3M | $318.8M |
| Q1 2023 | May 4, 2023 | −$1.67 | −$1.40 | 16.19% | $312.3M | $319.3M |
| Q4 2022 | Feb 23, 2023 | −$1.86 | −$1.68 | 9.64% | $313.1M | $335.0M |
| Q3 2022 | Oct 27, 2022 | −$1.74 | −$3.32 | -90.48% | $291.7M | $264.3M |
| Q2 2022 | Jul 28, 2022 | −$1.59 | −$2.29 | -44.47% | $255.6M | $224.8M |
| Q1 2022 | Apr 28, 2022 | −$1.81 | −$2.00 | -10.58% | $240.9M | $213.3M |
| Q4 2021 | Feb 10, 2022 | −$1.55 | −$2.16 | -39.70% | $233.6M | $258.5M |
| Q3 2021 | Oct 28, 2021 | −$1.54 | −$1.72 | -11.91% | $218.7M | $187.6M |

## Frequently Asked Questions

### When did Alnylam Pharmaceuticals (ALNY) last report earnings?

Alnylam Pharmaceuticals last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did ALNY beat earnings estimates?

No. Alnylam Pharmaceuticals reported EPS of $1.21 for Q2 2026 against a $1.63 estimate — a 25.78% miss.

### How much revenue did ALNY report last quarter?

Alnylam Pharmaceuticals reported $1.3B in revenue for Q2 2026, against a consensus estimate of $1.3B.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).